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Background/aim: The central nervous system is one of the major targets in lead exposure. Biomarkers for the diagnosis and follow-up
of lead exposure have not been identified. In this study, serum S100B, neuron-specific enolase (NSE), and glutamate receptor 1 (GRIA1)
levels were determined as possible biomarkers for lead neurotoxicity.
Material and methods: Twenty-five subjects with chronic lead exposure and 25 controls were included in the study. NSE and S100B
were measured by electrochemiluminescence immunoassay with a Cobas E601 analyzer. GRIA1 levels were measured with an ELISA
kit using a quantitative sandwich enzyme immunoassay technique.
Results: GRIA1 levels were significantly higher in the lead exposure group than in the control group. No significant differences for NSE,
S100B, ALT, AST, or creatinine in sera were found between lead exposure and control groups.
Conclusion: Subjects with chronic lead exposure are found to have increased glutamate receptor levels and do not seem to have glial or
neuronal damage, which can be demonstrated with the elevation of NSE and S100B levels. GRIA1 levels might be used as a biomarker
for the neurotoxicity of lead.
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1. Introduction
Lead (Pb) is a widespread heavy metal that can persist in
water, plants, and soil in the environment naturally in an
inert form (1). Human exposure can be associated with
the use of lead-containing ceramic dishware, food cans,
and paints or, more commonly, it may be occupational
in individuals working in industrial areas like automobile
batteries, paints, ceramics, plastics, and cosmetics (2,3).
The central nervous system (CNS) is a major target in
lead exposure. Lead is known to be a risk factor for a variety
of neurologic and psychiatric disorders. Lead-induced
brain injury appears to affect cognitive functions in the
frontal cortex, motor ability in the cerebellum, and memory
in the hippocampus (3,4). Several mechanisms are offered
for lead-induced neurotoxicity, including cholinergic
dysfunction, glutamate receptor changes, increased
oxidative stress, and impaired antioxidant defense system
in the brain (5). Lead acts like calcium in the CNS and
enters cells from calcium channels. Lead exposure causes
an elevation in intracellular calcium as the result of high
uptake to astrocytes. Lead also activates protein kinase C
* Correspondence: dr_esrafirat@hotmail.com

(PKC) like calcium and PKC activation leads to calcium
release from intracellular stores. This causes secretion of
excitatory neurotransmitters, phospholipase activation,
and oxidative stress in the CNS (6).
S100B is a biomarker with low molecular weight (9–13
kDa) and belongs to the calcium-binding protein family. It
is found in glial cells of the CNS, especially in astrocytes.
Neuron-specific enolase (NSE) is a glycolytic enzyme
found in neuronal cytoplasm and known as a biomarker
of brain damage with S100B. After neuronal damage,
their elevated levels are found in blood and cerebrospinal
fluid according to the increased permeability of the
blood–brain barrier (BBB) (7,8). Glutamate is one of the
major neurotransmitters in brain and affects N-methyld-aspartate (NMDA) receptor activation, which is
mediated by calcium. Glutamate receptors are divided
into two groups: the fast-acting ligand-gated ionotropic
channels and the slower-acting metabotropic receptors.
The ionotropic receptors are cation-specific ion channels.
These receptors are subdivided into three groups: α-amino3-hydroxy-5-methyl-4-isoxazolepropionate
(AMPA),
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kainate, and NMDA receptor channels (9). Glutamate
receptors are important for synaptic transmission during
learning and memory. AMPA receptors were demonstrated
to mediate most excitatory responses in the brain (10).
Some studies revealed that ionotropic NMDA receptors
have important roles in lead-induced neurotoxicity (11–
13).
Glutamate receptor 1 (GRIA1) is one of the ionotropic
excitatory receptors in mammalian brains and is important
in neural communication, learning, and memory (14).
GRIA1 is responsible for glutamate-mediated excitation
of neural cells and is important in memory formation
and learning. GRIA1 levels were investigated in acute
mercury intoxication and were suggested to be a potential
neurological biomarker in mercury-induced neurotoxicity
(15).
In this study, we aimed to study NSE, S100B, and
GRIA1 levels in subjects with chronic lead exposure and
determine whether these parameters could be used as
biomarkers of lead neurotoxicity.
2. Materials and methods
2.1. Patients
The exposure group consisted of workers in the battery
industry (n = 15) and smelters (n = 10), who were admitted
to the Ankara Occupational Diseases Hospital for annual
health examinations. The mean lead-related work duration
was 7.6 years for battery workers and 5.4 years for smelters.
Twenty-five healthy adults admitted to the hospital for
routine check-ups, without a history of occupational Pb
exposure and with normal physical examination and no
chronic illness, were included in the study as the control
group. Subjects with Pb exposure were divided into two
groups according to their neurological examination results.
This study was approved by the local ethics committee of
Ankara Keçiören Training and Research Hospital (date:
22.02.2012 / no.: B.10.4.ISM.4.06.68.49)
2.2. Blood samples and measurement
Venous blood samples were collected in vacutainer tubes
and centrifuged at 1300 × g for 10 min. Sera were separated
and stored at –20 °C until analysis.
GRIA1 was measured with an ELISA kit (Cusabio
Biotech Co., P.R. China; catalog number: CBSEL009898HU) using a quantitative sandwich enzyme
immunoassay technique. Detection range of the assay was
23.44–1500 pg/mL. Intra- and interassay precision were
<8% and <10%, respectively.
NSE (catalog number: REF 12133113 122) and S100B
(catalog number: REF 03175243 190) were measured by
electrochemiluminescence immunoassay in a Cobas E601
analyzer (serial number: 2115-01; Roche, Germany).
Detection range of the NSE assay was 0.050–370 ng/mL.
Detection range of the S100B assay was 0.005–39 µg/L.
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Repeatability of the S100B assay was 1.0%, 1.8%, and 0.7%
at concentrations of 0.09 µg/L, 0.26 µg/L, and 2.25 µg/L,
respectively. Reproducibility of the S100B assay was 3.1%,
2.5%, and 2.9% at concentrations of 0.09 µg/L, 0.26 µg/L,
and 2.24 µg/L, respectively. Repeatability of the NSE assay
was 1.6%, 0.8%, and 0.7% at concentrations of 0.90 ng/mL,
11.9 ng/mL, and 95.1 ng/mL. Reproducibility of the NSE
assay was 2.2%, 3.1%, and 3.8% at concentrations of 0.87
ng/mL, 11.4 ng/mL, and 87.3 ng/mL.
Whole-blood lead determination was performed
using EDTA tubes in the toxicology laboratory of the
Ankara Occupational Diseases Hospital using Varian AA
240Z (Agilent Technologies, Inc., Santa Clara, CA, USA)
atomic absorption spectrophotometry (serial number:
AA0904M070). Standard solutions were prepared by
dilution of certified standard solutions (High-Purity
Standards, Charleston, SC, USA). Two-level quality control
materials were used (Seronorm; Sero AS, Billingstad,
Norway). The lead calibration curve ranged from 0 to 100
µg/dL. Limits of detection and quantification were 0.02
and 0.1 µg/dL, respectively. The relative standard deviation
of measurements was 4.2%.
2.3. Statistical analysis
The findings of this study were analyzed with SPSS
18 (SPSS Inc., Chicago, IL, USA). The conformity of
continuous variables to normal distribution was tested
with the Kolmogorov–Smirnov test. The descriptive
statistics of continuous variables were expressed as median
(min–max). The presence of a statistically significant
difference between the groups in terms of continuous
variables was examined with the Mann–Whitney U test
for nonparametric variables. The presence of a correlation
between the groups was examined with Spearman’s rho
tests. P < 0.05 was considered the threshold of statistical
significance for all tests. The area under the curve (AUC),
specificity, and sensitivity values were calculated with
receiver operating characteristic (ROC) analysis.
3. Results
Subjects in the lead exposure group were 25–62 years
of age (median: 38) and those of the control group were
18–73 years of age (median: 37). In the lead exposure
group, the median blood lead level was 34.2 µg/dL with
a minimum value of 1.24 and a maximum value of 73.7
µg/dL. Mean exposure time was 6.21 ± 6.396 years. The
GRIA1 level was significantly higher in the lead exposure
group than in the control group (P = 0.011). No significant
difference was determined between the lead exposure and
the control group for NSE, S100B, ALT, AST, or creatinine
levels (P > 0.05) (Table 1).
Subjects who had lead exposure were divided into
two groups according to their neurological examinations.
Fourteen of the subjects had neurological signs in their
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examination. Twelve of these 14 subjects had pain and
numbness of the hands and others had pain and numbness
of the feet. Eleven of the subjects had no neurological signs
in their examination. There was no significant difference
in the levels of GRIA1, NSE, or S100B between these two
groups (P > 0.05) (Table 2).
There were no correlations between lead exposure
and GRIA1, NSE, S100B, ALT, AST, and creatinine levels
(Table 3).
ROC analysis was performed for GRIA1. The AUC for
GRIA1 was 0.709. Sensitivity and specificity for GRIA1
levels to detect lead-related neurotoxicity were found as
70% and 56%, respectively (cut-off: 39.1 pg/mL) (Figure).
4. Discussion
The CNS is a major target in lead exposure. Lead is known
to be a risk factor for a variety of neurologic and psychiatric
disorders.
In the present study, we studied the levels of
neurological biomarkers S100B, NSE, and GRIA1 in lead
exposure and control groups. We found that GRIA1 levels
were significantly higher in the lead exposure group.

However, according to ROC analysis, the sensitivity and
specificity values for GRIA1 levels to detect lead-induced
neurotoxicity did not indicate that it is a good biomarker.
GRIA1 is one of the excitatory receptors in mammalian
brains and is responsible for glutamate-mediated excitation
of neural cells. It is important in memory formation and
learning (14). Overactivation of glutamate receptors
AMPA and NMDA is involved in the process of cell
damage by increasing the intracellular Ca2+ concentration
in neurons and activating the generation of free radicals,
proteases, and phospholipases (16). These receptors are
thought to be vulnerable to effects of Pb as Pb mimics
calcium and activates PKC, this activation disturbing
the signaling mechanisms (17–19). Studies indicate that
Pb is accumulated in brain regions, especially in the
hippocampus and cerebellum (20–22). In the hippocampus
Pb affects Ca2+-dependent cellular processes. Studies
suggested the NMDA receptor as a target in lead-induced
neurotoxicity (11,23). In the present study, we think that
the finding of higher GRIA1 levels in the exposure group
support the literature findings and GRIA1 levels may be
thought to be a potential biomarker in lead neurotoxicity.

Table 1. Comparison of serum GRIA1, NSE, and S100B and routine chemical parameters of the
lead exposure and control groups
Lead exposure
group (n = 25)

Controls
(n = 25)

P

GRIA1 (pg/mL)

39.9 (33.5–64.5)

36.2 (32.0–51.2)

0.011*

NSE (ng/mL)

14.8 (10.6–35.4)

15.6 (4.9–30.0)

0.516

S100B (µg/L)

0.058 (0.026–0.160)

0.049 (0.027–0.135)

0.607

ALT (IU/L)

16 (3–91)

27 (11–52)

0.109

AST (IU/L)

18 (11–39)

21 (12–42)

0.662

Creatinine (mg/dL)

0.8 (0.6–1.3)

0.95 (0.77–1.25)

0.180

GRIA1, NSE, S100B, creatinine, ALT, and AST are expressed as median (min–max).
GRIA1: Glutamate receptor 1, NSE: neuron-specific enolase, ALT: alanine aminotransferase,
AST: aspartate aminotransferase.
Table 2. Comparison of groups with and without neurological signs.
Neurological
signs (+) (n = 14)

Neurological
signs (–) (n = 11)

P

GRIA1 (pg/mL)

41.9 (33.5–54.6)

39.4 (35.8–64.5)

0.584

NSE (ng/mL)

15.0 (10.6–35.4)

14.9 (11.0–22.0)

0.661

S100B (µg/L)

0.051 (0.026–0.160)

0.058 (0.042–0.079)

0.380

Lead (µg/dL)

36.3 (1.2–73.0)

29.4 (13.4–47.2)

0.228

GRIA1, NSE, S100B, and lead are expressed as median (min–max).
GRIA1: Glutamate receptor 1, NSE: neuron-specific enolase.
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Table 3. Correlation between blood lead levels and other
parameters.
Lead

r

P

GRIA1 (pg/mL)

–0.382

0.600

NSE (ng/mL)

0.107

0.611

S100B (µg/L)

–0.98

0.640

ALT (IU/L)

–0.074

0.726

AST (IU/L)

0.208

0.318

Creatinine (mg/dL)

–0.384

0.058

GRIA1: Glutamate receptor 1, NSE: neuron-specific enolase,
ALT: alanine aminotransferase, AST: aspartate aminotransferase.

However, there was no significant difference in the levels of
GRIA1 between the lead-exposed groups with and without
peripheral neurological signs and this result might be
related to GRIA1 levels indicating Pb exposure in the CNS
but not in the peripheral nervous system, as GRIA1 levels
are known to have important roles in the CNS (13). Basu
et al. also studied NMDA receptor levels in mink exposed
to mercury, another heavy metal, and found decreased
levels as a result of impaired glutamate homeostasis (24).
In another study GRIA1 levels were investigated in cases
of mercury exposure and were found to be higher than in
the control group. High levels of GRIA1 were related to
improvement of the neurological symptoms of exposed
patients and it was suggested as a potential neurological
biomarker in mercury-induced neurotoxicity (15).
On the other hand, no difference was found in terms
of S100B and NSE levels between groups. Lead can
cross the BBB by acting like calcium and accumulates
in astroglial cells, disturbs immature astroglial cells,
and blocks the formation of myelin sheath (2). During
toxic conditions, glial cells undergo some changes like
reactive gliosis. After glial reactions one of the most
affected markers is S100B. S100B has two roles according
to its levels. At nanomolar concentrations it acts as a
neuroprotective factor and at micromolar concentrations
it may act as a proinflammatory cytokine and promotes
neuroinflammatory reactions and neuronal dysfunction
(7). In our study we did not find a significant difference
in the levels of S100B between lead-exposed workers and
the control group. Marchi et al. measured S100B levels in
patients with iatrogenic BBB disruption by intraarterial
mannitol infusion and found that low levels of S100B
were associated with BBB opening without CNS damage.
High S100B release indicates synthesis and glial damage
(25). Pleines et al. studied patients with traumatic brain
injury (TBI) and found very low S100B levels in normal
individuals without brain injury (22). We thought that
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Figure. ROC curve for GRIA1.

in our lead-exposed group there was not glial damage in
the brain for S100B to act like a neuroprotective factor
and we therefore observed low levels of S100B. Zheng
et al. studied Pb-exposed workers and found that high
blood Pb concentrations were associated with significantly
lower sensory and motor conduction velocities in the
median, ulnar, and peroneal nerves (20). In neurological
examinations we saw peripheral neurological signs like
pain and numbness of the hands or feet in 10 participants,
but there was no significant difference between the two
groups. Bilińska et al. electrophysiologically recorded
the subclinical damage in the peripheral nervous system
in their study with asymptomatic workers chronically
exposed to inorganic Pb (9,21). In our study 9 of 14
participants who had positive neurological examinations
and complaints had electromyography as well and all of
them were found to be in normal ranges. S100B is usually
found in glial cells of the CNS in the largest amounts and
it increases with glial damage or activation. Therefore, a
reason for S100B to be nonsignificant might be that all
participants had peripheral neurological damage.
NSE is a glycolytic enzyme found in the cytoplasm of
neurons and neuroendocrine cells and shows functional
damage of neurons. Because of the high molecular weight
of NSE, it cannot pass through membranes. It is released
after cell destruction and increased concentrations can be
found in peripheral blood or liquor (7,26). Yardan et al.
studied S100B and NSE in patients with CO poisoning
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and found no elevation in levels of these parameters in
patients without loss of consciousness but significant
elevation in unconscious patients (26). Gradisek et al.
studied NSE and S100B in patients with TBI and found no
differences in concentrations of these biomarkers between
the group of survivors and patients who died because
of non-TBI causes (27). We did not find any significant
difference between lead exposure and control groups in
terms of NSE levels. In another study it was indicated that
protective features of the CNS prevent molecules from
passing through the peripheral circulation. Therefore, it

is recommended to evaluate behavioral and molecular
measurements with the results of biomarkers of exposure
to neurotoxicants (28).
In conclusion, the results of our study showed that
subjects with chronic lead exposure are found to have
increased glutamate receptor levels and do not seem to
have glial or neuronal damage, which can be demonstrated
with the elevation of NSE and S100B levels. GRIA1 levels
might be used as a biomarker for the neurotoxicity of lead.
Further studies are needed to identify the mechanisms
involved in the neurotoxicity of lead.
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